Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) reported Q2 EPS of $0.30, $0.01 worse than the analyst estimate of $0.31. Revenue for the quarter came in at $243.6 million versus the consensus estimate of $226.56 million.

GUIDANCE:

Kiniksa Pharmaceuticals, Ltd. sees FY2026 revenue of $980-995 million, versus the consensus of $940.1 million.

For earnings history and earnings-related data on Kiniksa Pharmaceuticals, Ltd. (KNSA) click here.